Metabolic Disorder Clinical Trial
Official title:
Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products
Verified date | September 2017 |
Source | Mondelez International, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aimed at determining the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products in two different ethnic groups.
Status | Completed |
Enrollment | 24 |
Est. completion date | April 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Aged between 18-45 years. - Non-smoker. - BMI values: between 19-25 kg/m2 (bounds included) for Caucasian subjects and between 19-23 kg/m2 (bounds included) for Asian subjects (WHO expert consultation). - Ethnicity: Caucasian subjects will have both parents from Caucasian ancestry. Asian subjects will have both parents from Asian country and will be born in an Asian country. Asian countries are: Brunei Darussalam, Cambodia, China, Dem. People's Republic of Korea, Hong Kong SAR (China), Indonesia, Japan, Lao People's Democratic Republic, Macao SAR (China), Malaysia, Mongolia, Myanmar, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Viet Nam. - Sex ratio: Around half of the subjects should be male and half of the subjects should be female within each study group. A plus or minus 1 subject tolerance will be accepted. - Healthy subjects with: Normal glucose tolerance Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol); Normal systolic blood pressure (100-150 mmHg); Normal diastolic blood pressure (60-90 mmHg); Normal resting heart rate (50-90 beats per minutes after 3 minutes rest). - Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting. - Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week)) - Able to fast for at least 10 hours the night before each test session. - Able to refrain from eating legumes and drinking alcohol the day before each test session. - Subject covered by social security or covered by a similar system - Subject not taking any treatment for anorexia, weight loss, or any form of treatment likely to interfere with metabolism or dietary habits - Subject having given written consent to take part in the study. Exclusion Criteria: - Following a restrictive diet. - Family history of Diabetes Mellitus or obesity - Suffering from any clinical, physical or mental illness. - Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc). - Taking any regular prescription medication at the time of inclusion (except regular oral contraception medication) - Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive. - Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle. - Subject having taken part in another clinical trial within the last week. - Subject currently taking part in another clinical trial or being in the exclusion period of another clinical trial. - Subject undergoing general anaesthesia in the month prior to inclusion. - Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject. |
Country | Name | City | State |
---|---|---|---|
Australia | University of Sydney | Sydney | New South Wales |
Lead Sponsor | Collaborator |
---|---|
Mondelez International, Inc. | University of Sydney |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glycaemic index values of five cereal products | Determination of GI in both Caucasian and Asian subjects | 2 hours after food consumption | |
Secondary | Glycaemic response assessed by the glycemic index (GI) values of five cereal products | Determination of GI in the global population | 2 hours after food consumption | |
Secondary | Glycaemic response assessed by the postprandial changes in glycaemia over 2 hours (iAUC0-120) after consumption of the test products | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Glycaemic response assessed by the kinetic of glycemia over the 120 minutes | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Glycaemic response assessed by the peak value of glycemia | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Glycaemic response assessed by the delta value between baseline and peak values of glycemia | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Insulinaemic response assessed by the insulinemic index (II) values of five cereal products | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Insulinaemic response assessed by the postprandial changes in insulinemia over 2 hours (iAUC0-120) after consumption of the test products | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Insulinaemic response assessed by the kinetic of insulinemia over the 120 minutes | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Insulinaemic response assessed by the peak value of insulinemia | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Insulinaemic response assessed by the delta value between baseline and peak values of insulinemia | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Insulin / glucose ratio (II/GI) evaluation of five cereal products | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Postprandial changes in insulin / glucose over 2 hours (iAUC0-120) after consumption of the test products | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Kinetic of insulin / glucose over the 120 minutes | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Peak value of insulin / glucose ratio | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption | |
Secondary | Delta peak value between baseline and peak values of insulin / glucose ratio | This parameter will be analyzed first in both Caucasian and Asian populations and second globally | 2 hours after food consumption |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00546052 -
A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
|
Phase 3 | |
Completed |
NCT00707746 -
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
|
Phase 2 | |
Completed |
NCT02573103 -
Air Pollution and Cardiovascular Disease
|
||
Not yet recruiting |
NCT06051461 -
Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication
|
N/A | |
Not yet recruiting |
NCT05013112 -
Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
|
N/A | |
Enrolling by invitation |
NCT04654000 -
Rheopheresis as Adjuvant Treatment of Calciphylaxis
|
N/A | |
Completed |
NCT01337141 -
A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients
|
N/A | |
Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
Recruiting |
NCT03882580 -
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
|
||
Active, not recruiting |
NCT01911091 -
Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)
|
N/A | |
Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT00362180 -
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
|
Phase 2 | |
Completed |
NCT03873948 -
Evaluation of Arginine in Periodontal and Cardiovascular Disease
|
||
Completed |
NCT01738061 -
A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan
|
N/A | |
Completed |
NCT02059993 -
The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease
|
N/A | |
Completed |
NCT06129578 -
Plant Protein Supplementation Within a Healthy Lifestyle Modulates Plasma Circulating Amino Acids and Improves the Health Status of Overweight Individuals
|
N/A | |
Completed |
NCT06331572 -
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
|
||
Completed |
NCT05255718 -
Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome
|
N/A | |
Completed |
NCT00694109 -
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
|
Phase 3 |